8-K: BioAffinity Directors Anderson, Joyce Not Seeking Re-election

Robert Anderson and Roby Joyce will not stand for re-election to the bioAffinity Technologies, Inc. Board of Directors at the upcoming 2026 Annual Meeting.

Summary

• Robert Anderson and Roby Joyce informed bioAffinity Technologies, Inc.'s Board of Directors on March 5, 2026, of their decision not to seek re-election.
• Their current terms on the Board will expire at the company's 2026 Annual Meeting of Stockholders, which is scheduled for April 30, 2026.
• The decisions by Mr. Anderson and Mr. Joyce were not due to any disagreements with the company regarding its operations, policies, or practices.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a largely neutral event, as the departures are amicable and part of a natural board cycle, with no underlying operational or strategic disagreements disclosed.

Positives

• The departing directors' decisions not to stand for re-election did not result from any disagreements with the company on matters relating to its operations, policies, or practices, indicating an amicable transition.

Negatives

• The departure of two directors could lead to a temporary loss of institutional knowledge or experience on the Board.

Future Outlook

The company anticipates the departure of Robert Anderson and Roby Joyce from the Board of Directors upon the expiration of their current terms at the 2026 Annual Meeting of Stockholders, scheduled for April 30, 2026.

Management Comments

• The decisions not to stand for re-election did not result from any disagreements with the Company on any matter relating to the Company's operations, policies or practices.

Industry Context

StockSavvy.ai notes that director departures, even amicable ones, are common in corporate cycles and can sometimes signal a board refresh or strategic shift, though this filing explicitly indicates no disagreements, suggesting a routine transition rather than a contentious event.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will experience a change in the composition of the Board of Directors, which is responsible for corporate oversight and strategic direction.

Next Steps

• The 2026 Annual Meeting of Stockholders, scheduled for April 30, 2026, where new directors will likely be elected to fill the vacancies.

Key Dates

Recommendation

The filing reports routine board changes with no stated disagreements, providing no new material information to alter an existing investment thesis. A 'hold' recommendation is appropriate as the core business outlook remains unchanged based on this filing.

Keywords

bioAffinity Technologies, BIAF, Board of Directors, director departure, corporate governance, SEC filing, 8-K